In tumors, increased MFAP2 expression has been validated in papillary thyroid cancer, hepatocellular carcinoma, ovarian cancer, melanoma and laryngeal squamous cell carcinoma21-26. This evidence concerns the gene MFAP2 and hepatocellular carcinoma.